Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October

Imported from official source

Announcement

Safety Classified by Officially

At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies. 

The Committee did not start or conclude any referral procedures. Information on ongoing safety referrals is provided in the ‘Ongoing referrals’ table below. 

Information on all topics discussed by the PRAC is available in the agenda.

Agenda of the PRAC meeting 28 September - 1 October 2026

Monthly figures for PRAC outcomes based on the draft agenda.

  • 9 safety signals: 5 started, 4 ongoing and concluded
  • 85 periodic safety update reports (PSURs) single assessments: 55 recommendations for centrally authorised medicines only, 27 recommendations for nationally authorised medicines only, 3 recommendations for PSURs including both centrally and nationally authorised medicines
  • 49 risk management plans (RMPs) for centrally authorised medicines: 10 RMPs reviewed for new medicines, 39 RMPs reviewed for authorised medicines
  • 16 post-authorisation safety studies (PASSs): 7 protocols for imposed and non-imposed studies reviewed, 9 results from imposed and non-imposed studies reviewed
  • 0 referrals: 0 started, 0 ongoing or concluding
  • Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine and an adverse event that warrants further investigation. Safety signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under 'Signal management'.
  • This is an extract. The publication continues at the source.

    Source: European Medicines Agency.

    Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october

    Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    This publication has changed since it was first published

    2 versions recorded. The original is kept in full — nothing is overwritten.

    1. v2 imported change on current
    2. v1 as first published on

    Provenance

    Organization
    European Medicines Agency — imported from official source
    Official source
    https://www.ema.europa.eu/en/news.xml RSS
    Imported
    October 03, 2026 20:30
    Versions
    2 recorded
    Identity
    https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-...

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.